Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer

Anouk C. de Jong, Marcel Segbers, Sui Wai Ling, Laura H. Graven, Niven Mehra, Paul Hamberg, Tessa Brabander, Ronald de Wit and Astrid A.M. van der Veldt
Journal of Nuclear Medicine October 2023, 64 (10) 1556-1562; DOI: https://doi.org/10.2967/jnumed.123.265489
Anouk C. de Jong
1Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;
2Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcel Segbers
2Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sui Wai Ling
2Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura H. Graven
2Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niven Mehra
3Department of Medical Oncology, Radboud UMC, Nijmegen, The Netherlands; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Hamberg
4Department of Internal Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tessa Brabander
2Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald de Wit
1Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Astrid A.M. van der Veldt
1Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;
2Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Data supplements

  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
    • Supplemental Video
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (10)
Journal of Nuclear Medicine
Vol. 64, Issue 10
October 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer
Anouk C. de Jong, Marcel Segbers, Sui Wai Ling, Laura H. Graven, Niven Mehra, Paul Hamberg, Tessa Brabander, Ronald de Wit, Astrid A.M. van der Veldt
Journal of Nuclear Medicine Oct 2023, 64 (10) 1556-1562; DOI: 10.2967/jnumed.123.265489

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer
Anouk C. de Jong, Marcel Segbers, Sui Wai Ling, Laura H. Graven, Niven Mehra, Paul Hamberg, Tessa Brabander, Ronald de Wit, Astrid A.M. van der Veldt
Journal of Nuclear Medicine Oct 2023, 64 (10) 1556-1562; DOI: 10.2967/jnumed.123.265489
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
  • Google Scholar

More in this TOC Section

  • First-in-Human Study of 18F-Labeled PET Tracer for Glutamate AMPA Receptor [18F]K-40: A Derivative of [11C]K-2
  • Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis
  • [11C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study
Show more Clinical Investigation

Similar Articles

Keywords

  • 68Ga-PSMA PET/CT
  • prostate cancer
  • 223Ra
  • response evaluation
SNMMI

© 2025 SNMMI

Powered by HighWire